300199 翰宇药业
已收盘 11-13 15:00:00
资讯
新帖
简况
翰宇药业(300199.SZ)：特立帕肽(H)注射液获得药品注册证书
智通财经网 · 11-13 16:17
翰宇药业(300199.SZ)：特立帕肽(H)注射液获得药品注册证书
翰宇药业：前三季度公司多肽原料药出口实现较快增长
证券之星 · 11-11
翰宇药业：前三季度公司多肽原料药出口实现较快增长
翰宇药业：CRDMO业务正按战略部署稳步推进
证券之星 · 11-11
翰宇药业：CRDMO业务正按战略部署稳步推进
翰宇药业（300199）11月9日主力资金净卖出4713.36万元
证券之星 · 11-10
翰宇药业（300199）11月9日主力资金净卖出4713.36万元
翰宇药业（300199）11月5日主力资金净买入1.03亿元
证券之星 · 11-06
翰宇药业（300199）11月5日主力资金净买入1.03亿元
翰宇药业(300199.SZ)：HY3003片获得药物临床试验申请受理
智通财经 · 11-05
翰宇药业(300199.SZ)：HY3003片获得药物临床试验申请受理
翰宇药业(300199.SZ)：HY3003注射液获得美国FDA临床试验许可
智通财经 · 11-04
翰宇药业(300199.SZ)：HY3003注射液获得美国FDA临床试验许可
翰宇药业（300199）2026年三季报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 10-28
翰宇药业（300199）2026年三季报简析：营收净利润同比双双增长，应收账款上升
翰宇药业（300199）10月26日主力资金净卖出1.06亿元
证券之星 · 10-27
翰宇药业（300199）10月26日主力资金净卖出1.06亿元
翰宇药业(300199.SZ)：HY3003片剂临床前研究显示减重效果优于司美格鲁肽
智通财经 · 10-27
翰宇药业(300199.SZ)：HY3003片剂临床前研究显示减重效果优于司美格鲁肽
翰宇药业(300199.SZ)发布前三季度业绩，归母净利润4.37亿元，同比增长511.96%
智通财经 · 10-27
翰宇药业(300199.SZ)发布前三季度业绩，归母净利润4.37亿元，同比增长511.96%
翰宇药业：Q3净利2亿元，同比增369.76%，环比增83%
格隆汇 · 10-26
翰宇药业：Q3净利2亿元，同比增369.76%，环比增83%
翰宇药业最新公告：拟投资不超3.8亿元建设多肽药物产线扩建项目
证券之星 · 10-26
翰宇药业最新公告：拟投资不超3.8亿元建设多肽药物产线扩建项目
翰宇药业：公司重磅创新药品种HY3003片剂临床前研究显示减重效果优于司美格鲁肽
格隆汇 · 10-26
翰宇药业：公司重磅创新药品种HY3003片剂临床前研究显示减重效果优于司美格鲁肽
翰宇药业：公司及武汉原料药生产基地均已通过美国 FDA cGMP 现场检查
证券之星 · 10-21
翰宇药业：公司及武汉原料药生产基地均已通过美国 FDA cGMP 现场检查
翰宇药业：已建立包括高级结构表征在内的系统化研究平台
证券之星 · 10-20
翰宇药业：已建立包括高级结构表征在内的系统化研究平台
翰宇药业：公司在 AI 制药方向采取 "合作引进、分步落地" 的思路
证券之星 · 10-20
翰宇药业：公司在 AI 制药方向采取 "合作引进、分步落地" 的思路
翰宇药业：HY3003周制剂注射液国内临床试验申请已获受理
证券之星 · 10-20
翰宇药业：HY3003周制剂注射液国内临床试验申请已获受理
翰宇药业：公司替尔泊肽两项ANDA已向FDA递交并提交四段专利挑战声明
证券之星 · 10-20
翰宇药业：公司替尔泊肽两项ANDA已向FDA递交并提交四段专利挑战声明
翰宇药业：公司在复杂多肽药物领域已形成从原料药到制剂的一体化布局
证券之星 · 10-20
翰宇药业：公司在复杂多肽药物领域已形成从原料药到制剂的一体化布局
加载更多
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。公司共获得国内专利四百余项，国际专利数十项，各类多肽药物批件、新药证书和临床批件，配备国际领先的研发实验室及300余台（套）高端设备（如全自动合成系统、大容量纯化系统等），为国内领先。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":22.79,"timestamp":1794553395000,"preClose":23.05,"halted":0,"volume":38240511,"delay":0,"changeRate":-0.0113,"floatShares":745000000,"shares":883000000,"eps":0.455,"marketStatus":"已收盘","change":-0.26,"latestTime":"11-13 15:00:00","open":23.15,"high":23.85,"low":22.7,"amount":887000000,"amplitude":0.0499,"askPrice":22.8,"askSize":122,"bidPrice":22.79,"bidSize":26,"shortable":0,"etf":0,"ttmEps":0.455,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":23.05,"symbolType":"stock","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":25.36,"lowLimit":20.75,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":19,"roa":"--","peRate":50.087912,"roe":"52.19%","epsLYR":0.04,"committee":0.509227,"marketValue":20129000000,"turnoverRate":0.0513,"status":1,"floatMarketCap":16972000000},"requestUrl":"/m/hq/s/300199","defaultTab":"news","newsList":[{"id":"2683578521","title":"翰宇药业(300199.SZ)：特立帕肽(H)注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2683578521","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683578521?lang=zh_cn&edition=full","pubTime":"2026-11-13 16:17","pubTimestamp":1794557828,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的《药品注册证书》。特立帕肽是一种重组人甲状旁腺激素(1-34)类似物，适用于有骨折高发风险的绝经后妇女骨质疏松症的治疗。本品可显著降低绝经后妇女椎骨和非椎骨骨折风险。目前，国内已上市制剂企业有4家，包括EliLilly \nNederland B.V.等公司均为生物制品。公司特立帕肽(H)注射液为国内首个按化学合成路径获批的制剂。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astockgonggao/agugonggao2.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astockgonggao/agugonggao2.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1522826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0077","BK4142","H","300199","BK0239","BK0028","BK0070","BK4585","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682321437","title":"翰宇药业：前三季度公司多肽原料药出口实现较快增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2682321437","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682321437?lang=zh_cn&edition=full","pubTime":"2026-11-11 11:48","pubTimestamp":1794368887,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)11月10日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司前三季度多肽原料药出口同比增长很多，请问接下来在手原料药订单是否充足，能否保持住这个增速？翰宇药业回复：原料药业务方面，前三季度公司多肽原料药出口实现较快增长，武汉多肽产线扩建等产能项目按计划推进，为后续市场供应提供有力支撑。公司将持续深耕全球市场，丰富产品管线与客户结构，力争保持业务的良好发展态势，具体经营数据请以公司定期报告为准。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100022062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0070","BK0188","BK0028","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682214623","title":"翰宇药业：CRDMO业务正按战略部署稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2682214623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682214623?lang=zh_cn&edition=full","pubTime":"2026-11-11 11:48","pubTimestamp":1794368887,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业11月10日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100022063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0077","BK0028","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682535130","title":"翰宇药业（300199）11月9日主力资金净卖出4713.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682535130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682535130?lang=zh_cn&edition=full","pubTime":"2026-11-10 10:31","pubTimestamp":1794277884,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月9日收盘，翰宇药业报收于23.55元，下跌2.44%，换手率4.6%，成交量34.24万手，成交额8.26亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入9542.45万元，融资偿还8591.17万元，融资净买入951.28万元，连续3日净买入累计3343.28万元。翰宇药业主营业务：核心业务聚焦四大板块:多肽制剂、原料药、小核酸与CRDMO。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111000011684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0077","BK0239","BK0070","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681882377","title":"翰宇药业（300199）11月5日主力资金净买入1.03亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681882377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681882377?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:03","pubTimestamp":1793927015,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月5日收盘，翰宇药业报收于24.87元，上涨9.51%，换手率9.25%，成交量68.92万手，成交额16.79亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入1.39亿元，融资偿还1.29亿元，融资净买入1038.21万元。翰宇药业主营业务：核心业务聚焦四大板块:多肽制剂、原料药、小核酸与CRDMO。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600009277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300199","BK0239","BK0028","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681420550","title":"翰宇药业(300199.SZ)：HY3003片获得药物临床试验申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2681420550","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681420550?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:19","pubTimestamp":1793870396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，公司于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的关于HY3003片临床试验申请的《受理通知书》。HY3003片是公司布局的一款GLP-1R/GIPR/GCGR三重受体激动剂口服制剂，拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。HY3003项目采用多剂型并行的开发策略，开发方向包括HY3003注射液(周制剂)、HY3003缓释注射液(月制剂)以及HY3003片(每日一次的口服制剂)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","IBBJ","BK0077","BK0239","MDTX","BK0070","PSYK","BMED","300199","BK0188","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680038292","title":"翰宇药业(300199.SZ)：HY3003注射液获得美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2680038292","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680038292?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:19","pubTimestamp":1793780377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司于近日收到美国食品药品监督管理局下发的关于HY3003注射液的临床试验许可通知。FDA已完成对该IND申请的安全性审查，并同意公司按照提交的临床试验方案开展首次临床试验。该项目采用多剂型并行的开发策略，开发方向包括HY3003注射液(周制剂)、HY3003缓释注射液(月制剂)以及HY3003片剂。本次获得FDA临床试验许可的HY3003注射液为每周皮下注射给药一次。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0070","300199","BK0028","BK0239","BBC","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678374498","title":"翰宇药业（300199）2026年三季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2678374498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678374498?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:34","pubTimestamp":1793190857,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期翰宇药业发布2026年三季报。截至本报告期末，公司营业总收入12.42亿元，同比上升81.87%，归母净利润4.37亿元，同比上升511.96%。按单季度数据看，第三季度营业总收入5.54亿元，同比上升314.48%，第三季度归母净利润2.0亿元，同比上升369.76%。本报告期翰宇药业应收账款上升，应收账款同比增幅达277.32%。本文数据来源于翰宇药业2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800047700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678458361","title":"翰宇药业（300199）10月26日主力资金净卖出1.06亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678458361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678458361?lang=zh_cn&edition=full","pubTime":"2026-10-27 09:20","pubTimestamp":1793064011,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月26日收盘，翰宇药业报收于24.44元，下跌5.27%，换手率6.17%，成交量45.91万手，成交额11.42亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入1.42亿元，融资偿还9372.24万元，融资净买入4787.06万元。翰宇药业主营业务：核心业务聚焦四大板块:多肽制剂、原料药、小核酸与CRDMO。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700011605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0077","BK0239","BK0028","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678408118","title":"翰宇药业(300199.SZ)：HY3003片剂临床前研究显示减重效果优于司美格鲁肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2678408118","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678408118?lang=zh_cn&edition=full","pubTime":"2026-10-27 01:44","pubTimestamp":1793036662,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，公司近日完成了HY3003片剂减重适应症临床前药效学比较研究。研究结果显示，HY3003片剂对DIO小鼠及DIO大鼠肥胖模型均具有良好的减重效果，在同等实验条件下减重效果优于已上市的司美格鲁肽片剂，显示出该品种良好的开发前景。公告显示，HY3003片剂系公司布局的一款GLP-1R/GIPR/GCGR三重受体激动剂口服制剂，拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","BK0188","300199","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678190806","title":"翰宇药业(300199.SZ)发布前三季度业绩，归母净利润4.37亿元，同比增长511.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678190806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678190806?lang=zh_cn&edition=full","pubTime":"2026-10-27 00:36","pubTimestamp":1793032566,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布2026年三季度报告，前三季度，公司实现营业收入12.42亿元，同比增长81.87%。归属于上市公司股东的净利润4.37亿元，同比增长511.96%。归属于上市公司股东的扣除非经常性损益的净利润4.28亿元，同比增长741.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678606861","title":"翰宇药业：Q3净利2亿元，同比增369.76%，环比增83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678606861","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678606861?lang=zh_cn&edition=full","pubTime":"2026-10-26 19:32","pubTimestamp":1793014335,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0070","BK0188","BK0077","BK0028","BK0239","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678160649","title":"翰宇药业最新公告：拟投资不超3.8亿元建设多肽药物产线扩建项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2678160649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678160649?lang=zh_cn&edition=full","pubTime":"2026-10-26 19:30","pubTimestamp":1793014243,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司全资子公司武汉翰宇拟投资建设“B04与B06车间多肽药物产线绿色化智能化扩建项目”，投资规模不超过3.8亿元。项目建成后将新增年产多肽药物10吨产能。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600030549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0239","BK0070","300199","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678316708","title":"翰宇药业：公司重磅创新药品种HY3003片剂临床前研究显示减重效果优于司美格鲁肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2678316708","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678316708?lang=zh_cn&edition=full","pubTime":"2026-10-26 19:25","pubTimestamp":1793013940,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","300199","BK0077","159992","BK0070","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677717676","title":"翰宇药业：公司及武汉原料药生产基地均已通过美国 FDA cGMP 现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2677717676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677717676?lang=zh_cn&edition=full","pubTime":"2026-10-21 20:51","pubTimestamp":1792587067,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)10月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司（含武汉原料药基地）是否已被列入 FDA Import Alert 66-80 的 Green List？公司司美格鲁肽/替尔泊肽原料药对美出口是否受该进口警示影响？翰宇药业回复：尊敬的投资者，您好！公司及武汉原料药生产基地均已通过美国 FDA cGMP 现场检查，其中武汉原料药基地以 NAI（零缺陷）结论通过核查。公司将持续严格按照美国cGMP要求组织生产与出口，依法合规推进全球化布局。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100039156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0077","300199","BK0028","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676835696","title":"翰宇药业：已建立包括高级结构表征在内的系统化研究平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2676835696","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676835696?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:52","pubTimestamp":1792500731,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业10月20日在投资者关系平台上答复投资者关心的问题。公司在多肽质量研究方面已建立包括高级结构表征在内的系统化研究平台，可完成活性成分一致性、高级结构确证、杂质分析、稳定性评价等注册所需的体外表证工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0077","BK0028","300199","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676696859","title":"翰宇药业：公司在 AI 制药方向采取 \"合作引进、分步落地\" 的思路","url":"https://stock-news.laohu8.com/highlight/detail?id=2676696859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676696859?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:52","pubTimestamp":1792500731,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)10月20日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在AI制药领域有何前瞻性布局？翰宇药业回复：尊敬的投资者，您好！公司在 AI 制药方向采取 \"合作引进、分步落地\" 的思路，依托与碳云智肽的战略合作及战略参股；并结合多肽芯片、分子大模型和各类先进大模型开展创新分子的设计筛选，逐步搭建 \"AI + 多肽\" 研发平台。具体进展以公司正式公告为准，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300199","BK0188","BK0239","01477","BK0070","BK0077","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676968436","title":"翰宇药业：HY3003周制剂注射液国内临床试验申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2676968436","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676968436?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:52","pubTimestamp":1792500730,"startTime":"0","endTime":"0","summary":"能否介绍HY3003当前临床推进状态、差异化设计亮点，以及长期管线价值？HY3003系一款利用AI多肽芯片技术筛选出的GLP-1R/GIPR/GCGR三靶点受体激动剂，拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。目前周制剂注射液国内临床试验申请已获受理，美国 FDA 临床试验申请亦于近期获得受理。HY3003的后续进展及相关数据均以公司正式公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0070","BK0077","300199","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676696812","title":"翰宇药业：公司替尔泊肽两项ANDA已向FDA递交并提交四段专利挑战声明","url":"https://stock-news.laohu8.com/highlight/detail?id=2676696812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676696812?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:52","pubTimestamp":1792500730,"startTime":"0","endTime":"0","summary":"投资者提问：公司替尔泊肽两项ANDA于5月13日同步递交FDA并提交 Paragraph IV四段专利挑战，礼来是否在45天窗口期内发起诉讼？请介绍该事件对公司ANDA审评进程带来的积极影响，以及后续FDA审评、现场核查的准备情况？公司替尔泊肽两项ANDA已向FDA递交并提交四段专利挑战声明，目前处于受理审查阶段。公司将按FDA要求配合推进审评并做好相应准备，后续进展均以公司正式公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0028","300199","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676968176","title":"翰宇药业：公司在复杂多肽药物领域已形成从原料药到制剂的一体化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2676968176","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676968176?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:51","pubTimestamp":1792500719,"startTime":"0","endTime":"0","summary":"公司在复杂多肽药物领域已形成从原料药到制剂的一体化布局，在长链多肽的合成纯化，杂质的分析与管控、以及药物结构的研究确证、规模化放大、注册申报等方面积累了相应的自主技术能力，并通过高端制剂与包装的配套开发，保障产品从研发到商业化的稳定落地；利拉鲁肽、醋酸格拉替雷两款注射剂先后在美国获批并实现商业化，即是这一整体能力的体现，具体技术细节以公司公开披露为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0028","BK0188","BK0239","300199","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794683489197,"stockEarnings":[{"period":"1week","weight":-0.0559},{"period":"1month","weight":-0.084},{"period":"3month","weight":-0.1187},{"period":"6month","weight":-0.0244},{"period":"1year","weight":0.1378},{"period":"ytd","weight":0.2732}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"66412人(较上一季度减少1.31%)","perCapita":"11213股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。公司共获得国内专利四百余项，国际专利数十项，各类多肽药物批件、新药证书和临床批件，配备国际领先的研发实验室及300余台（套）高端设备（如全自动合成系统、大容量纯化系统等），为国内领先。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}